# Tesofensine Dosage Protocol Guide: Triple Reuptake Inhibitor Research (2026)
> Research Use Only (RUO) Disclaimer: Tesofensine is not approved by the FDA or any regulatory authority for human use. All information below is intended strictly for scientific research purposes. Not for human consumption, therapeutic use, or self-administration.
What Is Tesofensine?
Tesofensine (NS2330) is a triple monoamine reuptake inhibitor that blocks the reuptake of serotonin, norepinephrine, and dopamine simultaneously. Originally developed by NeuroSearch as a potential treatment for Parkinson's disease and Alzheimer's disease, tesofensine attracted intense research interest after Phase II clinical trials for obesity revealed dose-dependent weight loss of 6.5–12.8% over 24 weeks — among the highest magnitudes reported for any pharmacological intervention at the time.
The compound's multi-target mechanism distinguishes it from single-target agents like sibutramine (serotonin-norepinephrine reuptake inhibitor) or pure dopaminergic stimulants. By simultaneously amplifying three monoamine signaling pathways, tesofensine modulates appetite suppression, energy expenditure, and reward-driven eating behavior.
Mechanism of Action
Tesofensine inhibits presynaptic reuptake transporters for:
- •Serotonin (SERT): Increases synaptic serotonin, reducing appetite and improving satiety signaling
- •Norepinephrine (NET): Elevates norepinephrine, increasing metabolic rate and thermogenesis
- •Dopamine (DAT): Enhances dopamine signaling in reward pathways, reducing cravings for calorie-dense foods
This tri-modal action produces a synergistic anorectic and metabolic effect that research models suggest is greater than any single monoamine pathway could achieve alone. Animal studies also indicate that tesofensine may modulate hypothalamic neuropeptide Y (NPY) signaling — a key appetite-regulating circuit — contributing to its pronounced weight-loss effects.
Reconstitution Protocol
Tesofensine for research use is typically supplied as a lyophilized (freeze-dried) powder or as a pre-dissolved solution. Standard reconstitution for lyophilized material:
1. Solvent: Bacteriostatic water (BAC water) is the standard solvent for tesofensine reconstitution
2. Target concentration: Most research protocols target 0.5 mg/mL or 1.0 mg/mL concentrations
3. Reconstitution procedure:
- Allow vial to reach room temperature before opening
- Add BAC water slowly to the side of the vial wall — do not inject directly onto the powder
- Gently swirl (do not vortex or shake vigorously) until fully dissolved
- Solution should be clear and colorless
4. Storage: Reconstituted solutions are stable at 2–8°C for up to 4 weeks; lyophilized powder is stable at –20°C for up to 24 months
5. Sterility: Filter through a 0.22 µm syringe filter before use in cell or animal research
Research Dosing Ranges
Tesofensine research has been conducted across a dose range of 0.25–1.0 mg, with the most frequently cited research doses falling between 0.25 and 0.5 mg.
Clinical Trial Dosing (Human Studies)
The landmark TIPO-1 Phase II trial (Astrup et al., 2008, The Lancet) evaluated three doses over 24 weeks:
| Dose | Mean Weight Loss | Responders (≥5% loss) |
|---|---|---|
| 0.25 mg/day | 6.5% | 75% |
| 0.5 mg/day | 11.3% | 87% |
| 1.0 mg/day | 12.8% | 91% |
The 0.5 mg dose demonstrated an optimal benefit-to-risk ratio in this trial, with the 1.0 mg dose associated with higher rates of cardiovascular side effects including elevated heart rate and blood pressure.
Rodent Model Dosing
In preclinical obesity models, researchers have used:
- •Rats (diet-induced obesity): 0.5–2.0 mg/kg/day subcutaneous
- •Mice: 1.0–5.0 mg/kg/day intraperitoneal
- •Duration: Most protocols run 4–12 weeks for metabolic studies
Note that rodent weight-adjusted doses do not translate linearly to human equivalent doses; allometric scaling must be applied when designing translational research protocols.
Research Administration Protocols
Acute Research Protocol (Short-Term Mechanistic Studies)
- •Purpose: Characterizing monoamine reuptake inhibition kinetics, acute appetite suppression, or thermogenic response
- •Duration: 1–14 days
- •Dosing schedule: Once daily, consistent timing
- •Wash-in: Begin at lowest dose (0.25 mg equivalent) for 3–5 days before escalating in rodent models
Chronic Metabolic Research Protocol (Long-Term Weight Studies)
- •Purpose: Evaluating sustained weight loss, metabolic adaptation, or body composition changes
- •Duration: 4–24 weeks
- •Dosing schedule: Daily administration; consistency is critical for steady-state plasma levels
- •Monitoring: Bodyweight, food intake, metabolic markers, heart rate, blood pressure at defined intervals
Combination Protocol Considerations
Research has examined tesofensine in combination with β-adrenergic agonists (metoprolol) to attenuate cardiovascular side effects while preserving efficacy. Researchers studying combination protocols should include appropriate control groups and cardiovascular monitoring endpoints.
Pharmacokinetics
Understanding tesofensine pharmacokinetics is essential for designing research protocols:
- •Bioavailability: ~90% oral bioavailability in human studies
- •Time to peak (Tmax): ~2 hours post-dose
- •Half-life: ~220 hours (approximately 9 days) — tesofensine is a long-acting compound
- •Steady state: Reached at approximately 4–5 weeks of daily dosing
- •Metabolism: Primarily hepatic via CYP3A4; active metabolite M1 has similar pharmacological activity
- •Elimination: Primarily fecal (>85%)
The exceptionally long half-life means that steady-state plasma concentrations take weeks to achieve and that washout periods after study completion must be planned accordingly.
Safety Profile and Research Monitoring
Cardiovascular Effects
The primary dose-limiting adverse effects observed in clinical trials were cardiovascular:
- •Heart rate elevation: Observed at 0.5 mg and 1.0 mg doses; dose-dependent
- •Blood pressure: Modest increases in systolic and diastolic blood pressure
- •Monitoring recommendation: Cardiovascular parameters should be measured at baseline and at regular intervals throughout any research protocol
Psychiatric and Neurological Effects
Given tesofensine's mechanism across monoamine systems, researchers should monitor:
- •Signs of excessive dopaminergic stimulation (stereotypy in rodent models)
- •Sleep architecture changes in long-duration protocols
- •Mood-related behavioral endpoints in rodent anxiety/depression models if applicable
Drug Interaction Considerations for Research Design
Tesofensine research protocols should avoid concurrent administration of:
- •MAO inhibitors (risk of serotonin syndrome-like effects)
- •Other monoamine reuptake inhibitors (additive monoamine accumulation)
- •Strong CYP3A4 inhibitors (may elevate plasma tesofensine concentrations)
Cycling Framework for Chronic Research
Due to tesofensine's long half-life and the potential for monoamine system adaptation over time, research protocols typically use defined study periods rather than continuous indefinite administration:
- •Standard cycle: 8–24 week active period
- •Off period: Minimum 4–6 weeks to allow monoamine systems to return to baseline
- •Washout assessment: Verify endpoint biomarkers have returned to baseline before repeating
Current Research Landscape
As of 2026, tesofensine remains an active area of metabolic research. Key ongoing areas include:
1. Combination with GLP-1 agonists: Researchers are exploring whether tesofensine's central appetite-suppressing mechanism complements GLP-1's peripheral and central effects
2. Non-alcoholic fatty liver disease (NAFLD): Preliminary animal data suggests potential hepatoprotective effects alongside weight reduction
3. Cognitive function in obesity: Given tesofensine's original neurological target profile, research continues into potential cognitive benefits mediated through monoamine pathway optimization
Summary Table: Tesofensine Research Protocol Overview
| Parameter | Value |
|---|---|
| Compound class | SNDRI (triple reuptake inhibitor) |
| Research dose range | 0.25–1.0 mg/day (human-equivalent) |
| Administration route | Oral (research models); injectable for rodent studies |
| Half-life | ~220 hours (~9 days) |
| Steady-state | ~4–5 weeks |
| Cycle length | 8–24 weeks |
| Washout minimum | 4–6 weeks |
| Key monitoring | Heart rate, blood pressure, bodyweight, food intake |
| Storage (lyophilized) | –20°C up to 24 months |
| Storage (reconstituted) | 2–8°C up to 4 weeks |
Related Research Articles
- •Tesofensine: Triple Monoamine Reuptake Inhibitor Research Profile
- •GLP-1 vs GLP-2: Mechanism Differences and Research Applications
- •BPC-157 Dosage & Research Protocol Guide
---
This article is for informational and educational purposes only. Tesofensine is not approved for human use. All research involving tesofensine should comply with applicable institutional, national, and international regulations governing the use of research compounds.